Retatrutide 3D 60mg UAE: Pen Format, Clinical Development & Product Guide

Retatrutide 3D 60mg UAE is a product listing associated with retatrutide, an investigational compound being studied in clinical development. The supplied packaging identifies the product as RETATRUTIDE 3D, with 60mg/3ml shown on the box and states that one pen contains 5 doses.

Retatrutide is also known by the development code LY3437943 and is being investigated as a triple hormone receptor agonist involving GIP, GLP-1 and glucagon pathways. Current clinical development includes multiple Phase 3 and Phase 3b studies.

For UAE readers, it is important to distinguish an online product listing from an approved pharmaceutical medicine. The Abu Dhabi Department of Health issued a 2026 alert stating that retatrutide remained under clinical development and that unauthorized products were not licensed or authorized for use or distribution.

Quick Product Overview

Product Information

Details

Product

Retatrutide 3D

Compound

Retatrutide

Development code

LY3437943

Listed strength

60mg

Listed volume

3ml

Format

Pre-filled pen

Packaging statement

1 pen contains 5 doses

Label

For export only

Product category

Investigational compound

UAE context

Regulatory verification required

The product specifications above are taken from the supplied packaging. Current manufacturer, batch, storage and laboratory documentation should be verified separately.

What Is Retatrutide?

Retatrutide is an investigational molecule developed by Eli Lilly. Its scientific feature is activity across three hormone receptor pathways:

• GLP-1
• GIP
• Glucagon

Because of this combination, retatrutide is generally described as a triple agonist. Lilly states that it is still under investigation and has not been approved by a regulatory agency for public use.

The development code LY3437943 is commonly used in clinical-trial records and scientific references.

Understanding the 60mg/3ml Pen Format

The supplied packaging identifies this product as 60mg/3ml and states that one pen contains five doses.

That packaging information describes the physical product presentation. It should not be interpreted as a recommendation for how the product should be administered.

Different retatrutide products on the market can vary in strength, volume, pen design and documentation. Current UAE-oriented listings show several retatrutide pen formats, including 30mg, 40mg, 50mg and 60mg presentations.

For this reason, the exact product label and batch documentation should always be checked.

Retatrutide and Triple-Agonist Biology

Retatrutide is being investigated because it combines activity at three receptor systems.

GLP-1

GLP-1 signaling is associated with appetite regulation, satiety and glucose-related physiological processes.

GIP

GIP participates in glucose-dependent signaling and metabolic processes.

Glucagon

Glucagon is involved in energy metabolism and regulation of stored energy.

Researchers are studying whether simultaneous activity across these pathways can produce meaningful changes in metabolic outcomes. The triple-agonist mechanism is one of the central scientific features distinguishing retatrutide from single- and dual-pathway approaches.

Retatrutide Clinical Development

Retatrutide has progressed beyond early-stage research into a broad Phase 3 development program.

ClinicalTrials.gov records include studies examining:

• Obesity
• Obesity with type 2 diabetes
• Severe obesity with cardiovascular disease
• Weight-maintenance outcomes
• Dose-escalation strategies
• Comparisons with existing therapies

For example, TRIUMPH-5 is a Phase 3 study comparing retatrutide with tirzepatide in adults with obesity.

The existence of these studies demonstrates ongoing clinical development, but it does not mean that every retatrutide product available online is an approved medicine.

 Retatrutide 3D 60mg UAE and Weight-Management Studies

Body-weight change is one of the major outcomes being investigated in retatrutide trials.

Earlier Phase 2 research showed substantial average weight reductions at 48 weeks compared with placebo, while later Phase 3 studies have reported further results over longer follow-up periods.

Clinical findings should always be interpreted according to:

• Study population
• Dose studied
• Duration
• Comparator
• Primary endpoint
• Safety findings

A trial result represents an average outcome for a defined research population and does not guarantee the same result for an individual.

Retatrutide 3D Product Presentation

The supplied product image shows a clean pre-filled pen format with:

RETATRUTIDE 3D
60mg/3ml
1 pen contains 5 doses

The packaging also includes the phrase “For export only.”

These details are useful for product identification and cataloging, but packaging language does not establish regulatory approval, authenticity, purity or clinical suitability.

Product Verification and Documentation

When evaluating a retatrutide product, product-level documentation is particularly important.

Product Identity

Confirm the exact compound name and development code where applicable.

Strength and Volume

Verify that the labeled strength and volume correspond to the actual product.

Batch Information

Look for a lot or batch number.

Certificate of Analysis

A batch-specific COA can connect laboratory testing to a specific product lot.

Laboratory Testing

Available analytical documentation may include identity and purity testing. Current UAE peptide suppliers use COA and third-party testing as part of their product documentation.

Storage Documentation

Storage requirements should come from the exact manufacturer's or supplier's documentation.

Retatrutide 3D 60mg UAE and Regulatory Status

The UAE regulatory position is an important part of evaluating this product.

The Abu Dhabi Department of Health issued Circular 40/2026 warning healthcare facilities, healthcare professionals and the public against unauthorized retatrutide products. The circular states that retatrutide remained under clinical development and that unauthorized products were not licensed or authorized for use or distribution.

This means:

Online listing ≠ regulatory approval

Clinical development ≠ public authorization

Product availability ≠ official UAE medicine supply

For UAE readers, the current regulatory position should therefore be checked before relying on any retatrutide product listing.

How to Evaluate a Retatrutide Pen Listing

A professional product page should make verification straightforward.

Check the Label

Compare the product name, strength and volume with the listing.

Check the Batch

Look for batch or lot information where available.

Review Testing

Look for independent or batch-specific laboratory documentation.

Verify the Supplier

Confirm who manufactured or supplied the product.

Check Regulatory Information

Use current UAE authority information rather than relying on social-media or seller claims.

Frequently Asked Questions

What is Retatrutide 3D 60mg UAE?

It is a product listing identifying a RETATRUTIDE 3D pre-filled pen with 60mg/3ml shown on the supplied packaging.

How many doses does the package state?

The box states that one pen contains 5 doses.

What is LY3437943?

LY3437943 is the development code associated with retatrutide.

Why is retatrutide called a triple agonist?

Because it is being investigated across GIP, GLP-1 and glucagon receptor pathways.

Is retatrutide approved?

No. Lilly currently describes retatrutide as investigational, and the UAE Department of Health has warned against unauthorized retatrutide products.

What should I verify before evaluating this product?

Check the exact label, strength, volume, batch information, laboratory documentation, COA and current regulatory status.

Does the product packaging prove authenticity?

No. Packaging alone does not establish authenticity, purity, safety or regulatory authorization.

Conclusion

Retatrutide 3D 60mg UAE is a pre-filled pen presentation identified on the supplied packaging as 60mg/3ml, with the box stating that one pen contains five doses.

Retatrutide itself is an investigational triple agonist being studied across a growing Phase 3 and Phase 3b clinical program. Research includes obesity, type 2 diabetes, cardiovascular disease and other obesity-related conditions.

For UAE readers, the regulatory distinction is essential. The Abu Dhabi Department of Health has specifically warned against unauthorized retatrutide products and states that the compound remains under clinical development.

A reliable product page should therefore prioritize accurate product identification, transparent documentation, batch traceability and current regulatory information.